<DOC>
	<DOC>NCT01013064</DOC>
	<brief_summary>Study design: - Randomized, double-blind, placebo-controlled, sequential dose escalation - Six ascending dose cohorts are planned Primary Objective: - To evaluate the safety profile of single escalating intravenous dose levels of HM10760A</brief_summary>
	<brief_title>A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects</brief_title>
	<detailed_description>Secondary objectives: - To evaluate the dose response relationship of a single IV dose of HM10760A on pharmacodynamic parameters including hemoglobin, reticulocyte count, and reticulocyte hemoglobin content - To evaluate the pharmacokinetic profiles of single IV dose levels of HM10760A - To determine the pharmacologically active dose(PAD) of HM10760A - To assess the immunogenicity of a single IV dose of HM10760A</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 20 to 55 years Able and willing to provided written informed consent Hemoglobin &lt; 16 g/dL Prior exposure to EPO, darbepoetin, other EPO support proteins hypersensitivity to EPO, darbepoetin, E.coli derived proteins Hemoglobinopathy SBP &gt; 140 mmHg or &lt; 90 mmHg or DBP &gt; 95 mmHg Chronic, uncontrolled, or symptomatic inflammatory disease Malignancy(except nonmelanoma skin cancer)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Long acting</keyword>
	<keyword>EPO</keyword>
</DOC>